BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Renzulli M, Ramai D, Singh J, Sinha S, Brandi N, Ierardi AM, Albertini E, Sacco R, Facciorusso A, Golfieri R. Locoregional Treatments in Cholangiocarcinoma and Combined Hepatocellular Cholangiocarcinoma. Cancers (Basel) 2021;13:3336. [PMID: 34283065 DOI: 10.3390/cancers13133336] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Lu L, Zhang C, Yu X, Zhang L, Feng Y, Wu Y, Xia J, Chen X, Zhang R, Zhang J, Jia N, Zhang S, Granito A. The Value of Contrast-Enhanced Magnetic Resonance Imaging Enhancement in the Differential Diagnosis of Hepatocellular Carcinoma and Combined Hepatocellular Cholangiocarinoma. Journal of Oncology 2022;2022:1-11. [DOI: 10.1155/2022/4691172] [Reference Citation Analysis]
2 Goodwin B, Lou J, Butchy M, Wilson T, Atabek U, Spitz F, Hong Y. Hepatocellular-Cholangiocarcinoma Collision Tumors: An Update of Current Management Practices. The American Surgeon. [DOI: 10.1177/00031348221124323] [Reference Citation Analysis]
3 Roderburg C, Essing T, Kehmann L, Krieg S, Labuhn S, Kandler J, Luedde T, Loosen SH. Current Trends in Inpatient Care and In-Hospital Mortality of Cholangiocarcinoma in Germany: A Systematic Analysis between 2010 and 2019. Cancers (Basel) 2022;14:4038. [PMID: 36011031 DOI: 10.3390/cancers14164038] [Reference Citation Analysis]
4 Wang W, Li J, Liang B, Lv X, Zhu R, Wang J, Huang Z, Yang S, Zhang E. Anatomical liver resection improves surgical outcomes for combined hepatocellular-cholangiocarcinoma: A propensity score matched study. Front Oncol 2022;12:980736. [DOI: 10.3389/fonc.2022.980736] [Reference Citation Analysis]
5 Ding X, Li G, Sun W, Shen Y, Teng Y, Xu Y, Li W, Liu M, Chen J. Sintilimab Combined with Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma in Second-Line Setting—A Multi-Center Observational Study. Front Oncol 2022;12:907055. [DOI: 10.3389/fonc.2022.907055] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Saito N, Hatanaka T, Nakano S, Hazama Y, Yoshida S, Hachisu Y, Tanaka Y, Yoshinaga T, Kashiwabara K, Kubo N, Hosouchi Y, Tojima H, Kakizaki S, Uraoka T. A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab. Clinical Case Reports 2022;10. [DOI: 10.1002/ccr3.6129] [Reference Citation Analysis]
7 Abdelrahim M, Al-rawi H, Esmail A, Xu J, Umoru G, Ibnshamsah F, Abudayyeh A, Victor D, Saharia A, Mcmillan R, Al Najjar E, Bugazia D, Al-rawi M, Ghobrial RM. Gemcitabine and Cisplatin as Neo-Adjuvant for Cholangiocarcinoma Patients Prior to Liver Transplantation: Case-Series. Current Oncology 2022;29:3585-94. [DOI: 10.3390/curroncol29050290] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Gönül Geyik Ö, Anichini G, Ulukaya E, Marra F, Raggi C. DNA Damage Response Inhibitors in Cholangiocarcinoma: Current Progress and Perspectives. Cells 2022;11:1463. [DOI: 10.3390/cells11091463] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Nanashima A, Hiyoshi M, Imamura N, Yano K, Hamada T, Kai K. Recent Advances in Photodynamic Imaging and Therapy in Hepatobiliary Malignancies: Clinical and Experimental Aspects. Curr Oncol 2021;28:4067-79. [PMID: 34677263 DOI: 10.3390/curroncol28050345] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]